What is TWST's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 10.52B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for TWST?

P/E (TTM) is n/a and 52-week range is $23.30 to $219.71 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s TWST figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for TWST?

The company profile lists revenue (TTM) near $431M, net income (TTM) near $-13.64B, EPS (TTM) near $-2.22 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Twist Bioscience Corp based, and what identifiers does Chartloom list?

The company context section lists headquarters in South San Francisco, California, US, 62.3M shares outstanding, ISIN US90184D1000 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Twist Bioscience Corp

$TWST

Health Care · Biotechnology

IR Run Scenarios

$159.78

+5.08%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Twist Bioscience Corp. engages in the development of a proprietary semiconductor-based synthetic DNA manufacturing process. The company is headquartered in South San Francisco, California and currently employs 979 full-time employees. The company went IPO on 2018-10-31. The firm's proprietary silicon-based platform delivers precision, scale, and speed, supporting consistent, high-quality performance across a range of applications. The Company’s platform is a differentiated method of manufacturing synthetic deoxyribonucleic acid (DNA) by writing DNA on a silicon chip. By integrating proprietary hardware, software, and scalable infrastructure, including its e-commerce platform. The firm has extended this platform beyond DNA synthesis to offer an integrated portfolio that includes synthetic genes, next-generation sequencing, applications, sample preparation tools, antibody libraries, and biologic discovery services. Leveraging the same platform, it also manufactures synthetic ribonucleic acid (RNA) and expresses antibody proteins.

Employees

979

Website

www.twistbioscience.com/

IPO

2018-10-31

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)